Navigation Links
Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
Date:10/21/2008

TSX Exchange Symbol: RVX

CALGARY, Oct. 21 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that the ongoing double blind placebo controlled Phase 1b/2a study in subjects with normal and low HDL is progressing as planned. The subjects in the first group receiving a low dose of RVX-208 show safety and tolerability. Thus the safety committee the has made a decision to commence the next cohort in which 24 subjects will receive treatment doses escalating each week, for a total of 4 weeks.

Donald J. McCaffrey, President and CEO of Resverlogix stated, "We are very pleased to be able to share this exciting clinical information with the Clinical Advisory Board at the American Heart Association meeting on November 8th."

Resverlogix will give an oral presentation during the American Heart Association Scientific Sessions meeting in November 2008 where the Company will present novel data for RVX-208 to attendees. Due to the nature of double blinded clinical trials and strict embargo rules set by the American Heart Association, data from this Phase 1b/2a clinical trial will not be presented in full until the completion of the trial.

About RVX-208

RVX-208, a novel small molecule therapeutic that facilitates endogenous ApoA-I production, is positioned to be one of the most promising emerging drugs in the treatment of atherosclerosis. To the Company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production and thereby raise HDL levels thus enhancing HDL functionality to augment reverse cholesterol transport (RCT).

RCT is a pathway by which accumulated cholesterol is transported from the arterial wall to the liver for excretion, thus preventing atherosclerosis. Major constituents of RCT include acceptors such as high-density lipoprotein (HDL) and apolipoprotein A-I (ApoA-I). A critical part of RCT is cholesterol efflux, in which accumulated chole
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Resverlogix Announces Closing of Debt Redemption
2. Resverlogix Eliminates Sixty Percent of Remaining Debt
3. Resverlogix Issues a Management Statement
4. Resverlogix Board of Directors Update
5. Resverlogix Notice of Conference Call & Webcast
6. Jan Gray Joins Resverlogix Board of Directors
7. Resverlogixs Lead Drug Featured in Key Scientific Publication
8. Industry Leaders Select Resverlogixs RVX-208
9. /C O R R E C T I O N from Source -- Resverlogix Corp./
10. Resverlogix Notice of Conference Call & Webcast
11. Resverlogix Share Option Extension

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... Ambassador to Speak at Economic Club o...a (Vocus) November 25, 2009 -- Ambassador to Speak...Appia, French Ambassador for International Investm...Agency ,To view a biography of David Appia go to ...ppia is available to meet with press to discuss re...
(Date:11/25/2009)...G,Nov.25/PRNewswire-Asia/--SinovacBiotechLtd.(SVA)...todaythatitexecuted,ajointventure(JV)agreementtoes...inovacDalian).TheJVwillresearch,develop,produce,an...uteitsexpertise,andexperienceindevelopingandcommer...ngitslanduserights,manufacturingfacilitiesand,esta...
(Date:11/24/2009)...e is available in German . , Whether it,s C...FID tags (Radio Frequency Identification) are incr...y make it possible to label objects or goods and i... appropriate scanner can read and process the data...ed to goods under production conditions of up to 1...
(Date:11/24/2009)... The New York investment bank KTA Capit...as agreed an AU$6.7 mil convertible note private p...rivate placement was arranged by KTA Capital as Ne... New York (PRWEB) November 2...k KTA Capital, LLC ("KTA Capital") has a...
Breaking Biology Technology:French Ambassador for International Investment to Visit Toronto December 11 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3Intelligence inside metal components 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2
...EADseeker • imagin g • automatio n &bu...r™ Multimodality Imaging System is a CCD-bas...ects and quantitates light from a range of radiome...ghput of over 100 plates per hour is possible due ...cence assays can be read in as little as 10 s) and...
...omatostatin • receptor binding assay •... , Somatostatin (SS) is a neurotransmitter/...–3) and a reduction in cortical SS levels ha...’s diseases. The SS analog, octreotide (SMS ...t of certain tumors, carcinoid syndrome, and gluca...
...malin-fixed paraffin-embedded (FFPE),• Gen...• degenerate oligonucleotideprimed PCR (DOP-...comparative,genomic hybridization (CGH) • ...l; array CGH , , Human genom...ded (FFPE) tissue samples was amplified using the ...
Other Biology Technology:Integration of the LEADseeker Multimodality Imaging System with automated plate loading and incubation using Overlord Instrument software 2Integration of the LEADseeker Multimodality Imaging System with automated plate loading and incubation using Overlord Instrument software 3Integration of the LEADseeker Multimodality Imaging System with automated plate loading and incubation using Overlord Instrument software 4The development of a somatostatin sst4 receptor-binding assay using the LEADseeker Multimodality Imaging System 2The development of a somatostatin sst4 receptor-binding assay using the LEADseeker Multimodality Imaging System 3The development of a somatostatin sst4 receptor-binding assay using the LEADseeker Multimodality Imaging System 4The development of a somatostatin sst4 receptor-binding assay using the LEADseeker Multimodality Imaging System 5GenomiPhi amplification of FFPE tissue DNA for array CGH 2GenomiPhi amplification of FFPE tissue DNA for array CGH 3GenomiPhi amplification of FFPE tissue DNA for array CGH 4GenomiPhi amplification of FFPE tissue DNA for array CGH 5GenomiPhi amplification of FFPE tissue DNA for array CGH 6GenomiPhi amplification of FFPE tissue DNA for array CGH 7GenomiPhi amplification of FFPE tissue DNA for array CGH 8GenomiPhi amplification of FFPE tissue DNA for array CGH 9GenomiPhi amplification of FFPE tissue DNA for array CGH 10
(Date:11/24/2009)...cket science is opening new doors to understanding...t the hearing of a marine mammal or if they hear ...ized X-ray scanners that NASA uses to detect flaws...s is now allowing scientists to peek inside the gi...led three-dimensional replicas of a whale,s hearin...
(Date:11/24/2009)...ringer and the American College of Medical Toxicol... on the publication of the Journal of Medical Tox...beginning in March 2010. It was previously publis...The Journal of Medical Toxicology , an internatio...ing the science and practice of medical toxicology...
(Date:11/24/2009)...mbridge, Md. (November 24, 2009) New research on ...river ecosystems reveals predictable temporal patt...ommunities as markers for monitoring climate chang...week in the Proceedings of the National Academy o...mmunities in the six rivers shifted synchronously ...
Breaking Biology News(10 mins):Rocket science leads to new whale discovery 2Springer and the American College of Medical Toxicology to work together 2Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2CareGuide Adds New Management Team Members 51470 1CareGuide Adds New Management Team Members 51470 2Sit n Sleep Refocuses on Consumer Sleep Health and Well Being 51466 1Sit n Sleep Refocuses on Consumer Sleep Health and Well Being 51466 2Sit n Sleep Refocuses on Consumer Sleep Health and Well Being 51466 3Sit n Sleep Refocuses on Consumer Sleep Health and Well Being 51466 4Sparta Systems TrackWise 28R 29 Solution Delivers Workforce Training and Learning Initiatives for Cangene Corporation 12990 1Sparta Systems TrackWise 28R 29 Solution Delivers Workforce Training and Learning Initiatives for Cangene Corporation 12990 2Sparta Systems TrackWise 28R 29 Solution Delivers Workforce Training and Learning Initiatives for Cangene Corporation 12990 3Sparta Systems TrackWise 28R 29 Solution Delivers Workforce Training and Learning Initiatives for Cangene Corporation 12990 4
... The Stowers Institute,s Rong Li Lab has discove... in inflammation may also have a role in the forma...ney Disease (ADPKD) one of the most common life-t...drug inhibiting the protein can slow the disease i...dvance online publication of Nature Medicine yes...
... CORVALLIS, Ore. A major initiative to create al...Caspian terns in the world and to help protect ju... is finding early success. , A recent survey of a..., which was just constructed in February by the U....sting pairs of Caspian terns, as well as more than...
... Hamilton, ON. June 16, 2008 Single person subme...rieve samples from a lake in northern British Colu...ife on Earth and on other planets. , Greg Slater,...ence, says the objects of scientific interest are ...alites because they are covered with microbes. Som...
Other Biology News:Rong Li Lab identifies new role of inflammatory protein in PKD and a possible treatment 2Project succeeding to relocate Caspian terns 2Project succeeding to relocate Caspian terns 3Project succeeding to relocate Caspian terns 4Project succeeding to relocate Caspian terns 5Project succeeding to relocate Caspian terns 6Mini subs to probe odd structures in BC lake 2
...cture from 3 to 4 week old rabbits (New Zealand Wh... at -70C. The complement is thawed, pooled, steril...DIRECT SALES FROM PEL-FREEZ BIOLOGICALS! IF YOU HA...UY DIRECTLY FROM THE SOURCE! FORMER DISTRIBUTORS A...
Thermal Grayscale USB Printer for Imaging Systems; USB Connection from Alpha Innotech
GIBCO Newborn Calf Serum Heat-Inactivated from Invitrogen
Ready-To-Use IHC Bluing Reagent from Bethyl Laboratories
Biology Products: